Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 15 of 15 for “"BCG immunotherapy"”.

  1. Local immunopotentiation of the bladder in response to BCG immunotherapy

    Although intravesical Bacillus Calmette-Gu??rin (BCG) therapy for superficial bladder cancer is the most successful example of cancer immunotherapy, much remains unknown about its mechanisms of action.Using a standardized protocol for measuring urinary cytokines, we noted that BCG induces a mixed …

    nus Repository record for Local immunopotentiation of the bladder in response to BCG immunotherapy (opens in a new tab) Download file for Local immunopotentiation of the bladder in response to BCG immunotherapy (opens in a new tab)

  2. Investigating the Autoimmune Basis of Poor Response to BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer

    Bacillus Calmette-Guerin (BCG) immunotherapy remains the standard treatment for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC); however, many patients fail to respond and experience recurrence or progression to higher stages. The immune system is shaped by biological …

    queens Repository record for Investigating the Autoimmune Basis of Poor Response to BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer (opens in a new tab)

  3. COMBINING BCG IMMUNOTHERAPY WITH STING PATHWAY ACTIVATION TO INDUCE TERTIARY LYMPHOID STRUCTURES IN THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER

    … with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. BCG is the live-attenuated form of Mycobacterium bovis and is utilized in an adjuvant setting to recruit immune cells and potentiate anti-tumor immunity. Like other mucosal sites, the bladder has the potential to harbor immune …

    queens Repository record for COMBINING BCG IMMUNOTHERAPY WITH STING PATHWAY ACTIVATION TO INDUCE TERTIARY LYMPHOID STRUCTURES IN THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (opens in a new tab)

  4. Investigating the Role of Trained Immunity in Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer Using a Mouse Model

    … adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy following transurethral resection of bladder tumour (TURBT). BCG is a live-attenuated form of Mycobacterium bovis and is utilized in an adjuvant setting to potentiate antitumour immunity. However, the mechanism of action by which …

    queens Repository record for Investigating the Role of Trained Immunity in Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer Using a Mouse Model (opens in a new tab)

  5. Investigating Aging-Associated Loss of Sex Chromosomes in Immune Cells and Response to Bacillus Calmette-Guérin Immunotherapy in Bladder Cancer

    Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains the standard treatment for intermediate- and high-risk non-muscle invasive bladder cancer. Unfortunately, up to 60% of patients experience recurrence or progression. Older age and female sex are associated with poor response to BCG, …

    queens Repository record for Investigating Aging-Associated Loss of Sex Chromosomes in Immune Cells and Response to Bacillus Calmette-Guérin Immunotherapy in Bladder Cancer (opens in a new tab)

  6. Age-associated mucosal and systemic immunomodulation by Bacillus Calmette-Guérin immunotherapy in Non-Muscle Invasive Bladder Cancer

    … cases. Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains the standard of care for high-risk NMIBC, however clinical outcomes remain suboptimal. This limited efficacy is largely attributed to an incomplete understanding of mucosal and systemic immune responses triggered by …

    queens Repository record for Age-associated mucosal and systemic immunomodulation by Bacillus Calmette-Guérin immunotherapy in Non-Muscle Invasive Bladder Cancer (opens in a new tab)

  7. TARGETED THERAPY FOR UROLOGIC MALIGNANCIES

    … to intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle-invasive bladder cancer (BC) patients, by performing single nucleotide polymorphisms analysis of their peripheral blood DNA. We show that patients with NRAMP1 (D534N and (GT)n genotypes) and hGPX1 gene polymorphisms …

    nus Repository record for TARGETED THERAPY FOR UROLOGIC MALIGNANCIES (opens in a new tab) Download file for TARGETED THERAPY FOR UROLOGIC MALIGNANCIES (opens in a new tab)

  8. Effects of lactobacillus on normal and tumour bearing mice

    Mycobacterium bovis, Bacillus Calmette Guerin (BCG) immunotherapy is the current gold standard for superficial bladder cancer treatment but has a non-responder rate of 30 - 50% and side-effects are common. Using the murine orthotopic bladder cancer model, Lactobacillus rhamnosus GG (LGG) …

    nus Repository record for Effects of lactobacillus on normal and tumour bearing mice (opens in a new tab) Download file for Effects of lactobacillus on normal and tumour bearing mice (opens in a new tab)

  9. MAIT cells in sterile and non-sterile inflammation

    … also determined that MAIT cells may respond to BCG immunotherapy of bladder cancer, as they are both present and activated in the bladder following treatment. Finally, we wanted to determine the extent to which both the TCRα and TCRβ usage affected MAIT cell responses. We found that the TRAJ …

    oxford Repository record for MAIT cells in sterile and non-sterile inflammation (opens in a new tab)

  10. Prognostic Features of Non-Muscle-Invasive Bladder Cancer: Grade, Molecular Subtype and Tumour Immune Microenvironment

    … in prognoses and sensitivities to intravesical BCG immunotherapy. Current research suggests that clinical outcomes may be attributed to differences in the tumour immune microenvironment (TIME) of NMIBC patients, including immune cell populations such as CD3+/CD8+ T-cells, M2 macrophages and …

    queens Repository record for Prognostic Features of Non-Muscle-Invasive Bladder Cancer: Grade, Molecular Subtype and Tumour Immune Microenvironment (opens in a new tab)

  11. Investigating Sexual Dimorphism in Murine Bladders and Plasmacytoid Dendritic Cell Response to BCG and STING Pathway Activation

    … a more aggressive disease, a poorer response to immunotherapy, and suffer worse clinical outcomes. Treatment with Bacillus Calmette-Guerin (BCG) immunotherapy is the mainstay for non-muscle invasive bladder cancer (NMIBC) treatment. Unfortunately, over 50% of patients do not respond optimally and …

    queens Repository record for Investigating Sexual Dimorphism in Murine Bladders and Plasmacytoid Dendritic Cell Response to BCG and STING Pathway Activation (opens in a new tab)

  12. Investigating the Link Between Recurrent Urinary Tract Infection Associated Immune Exhaustion and Bladder Cancer Progression

    … Although intravesical Bacillus Calmette-Guérin (BCG) remains the standard immunotherapy for intermediate- and high-risk non-muscle-invasive BC, treatment failure remains common, particularly in patients with a pre-existing dysfunctional or immunosuppressive tumour immune microenvironment. …

    queens Repository record for Investigating the Link Between Recurrent Urinary Tract Infection Associated Immune Exhaustion and Bladder Cancer Progression (opens in a new tab)

  13. RECOMBINANT BCG OVEREXPRESSING C-DI-AMP DEMONSTRATES ENHANCED IMMUNOGENICITY AND ENHANCED ANTI-TUMOR CYTOTOXICITY IN MNU-INDUCED BLADDER CANCER

    … several cancers. Intravesical instillation of BCG remains at the heart of bladder cancer immunotherapy to specifically treat the non-muscle invasive forms of this tumor (NMIBC) that accounts for more than 75% of the cases. Besides being an effective immunodominant antigenic vessel, BCG combined …

    jhu Repository record for RECOMBINANT BCG OVEREXPRESSING C-DI-AMP DEMONSTRATES ENHANCED IMMUNOGENICITY AND ENHANCED ANTI-TUMOR CYTOTOXICITY IN MNU-INDUCED BLADDER CANCER (opens in a new tab)